uniQure Q3 net loss narrows 24% to USD 61.22 million
Bitget2026/11/04 12:16- uniQure’s third-quarter 2026 net loss narrowed 24% year over year to $61.22 million.
- Revenue rose 40% year over year to $5.2 million due to higher license revenue.
- Cash, cash equivalents and investment securities totaled $768.4 million at September 30, 2026, sufficient to fund projected operating expenses into 2030.
- The FDA granted priority review to AMT-130 for Huntington’s disease, with a May 1, 2027, target action date.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Crypto prices
More
